|
GENVOYA(elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)tablets(三十五)
the white part of your eyes turns yellow, dark "tea-colored" urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomach-area pain.
The most common side effect of GENVOYA is nausea.
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of GENVOYA. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store GENVOYA?
Store GENVOYA below 86 °F (30 °C).
Keep GENVOYA in its original container.
Keep the container tightly closed.
Keep GENVOYA and all medicines out of reach of children.
General information about the safe and effective use of GENVOYA.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use GENVOYA for a condition for which it was not prescribed. Do not give GENVOYA to other people, even if they have the same symptoms you have. It may harm them.
You can ask your healthcare provider or pharmacist for information about GENVOYA that is written for health professionals.
For more information, call 1-800-445-3235 or go to www.GENVOYA.com.
What are the ingredients in GENVOYA?
Active ingredients: elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
Inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, silicon dioxide, and sodium lauryl sulfate. The tablets are film-coated with a coating material containing FD&C Blue No. 2/indigo carmine aluminum lake, iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.
Manufactured and distributed by: Gilead Sciences, Inc. Foster City, CA 94404
GENVOYA, EMTRIVA, STRIBILD, TRUVADA, TYBOST, and VITEKTA are trademarks of Gilead Sciences, Inc., or its related companies. ATRIPLA is a trademark of Bristol-Myers Squibb & Gilead Sciences, LLC. All other trademarks referenced herein are the property of their respective owners.
© 2017 Gilead Sciences, Inc. All rights reserved.
207561-GS-006
PRINCIPAL DISPLAY PANEL - 30 TABLET BOTTLE LABEL
NDC 61958-1901-1
30 tablets
Genvoya®
(elvitegravir, cobicistat,
emtricitabine, and tenofovir
alafenamide) Tablets
150 mg/150 mg/200 mg/10 mg
Note to pharmacist:
Do not cover ALERT box with pharmacy label.
ALERT: Find out about medicines that
should NOT be taken with Genvoya®
Principal Display Panel - 30 Tablet Bottle Label
CLOSE
INGREDIENTS AND APPEARANCE
GENVOYA
elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide tablet
PRODUCT INFORMATION
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:61958-1901
Route of Administration ORAL
ACTIVE INGREDIENT/ACTIVE MOIETY
Ingredient Name Basis of Strength Strength
elvitegravir (UNII: 4GDQ854U53) (elvitegravir - UNII:4GDQ854U53) elvitegravir 150 mg
cobicistat (UNII: LW2E03M5PG) (cobicistat - UNII:LW2E03M5PG) cobicistat 150 mg
emtricitabine (UNII: G70B4ETF4S) (emtricitabine - UNII:G70B4ETF4S) emtricitabine 200 mg
tenofovir alafenamide fumarate (UNII: FWF6Q91TZO) (tenofovir anhydrous |
|
